Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A new analysis of the OCEANIC-STROKE trial shows that asundexian, a novel factor XIa inhibitor, reduces recurrent ischemic stroke risk consistently across all cardiovascular risk levels — no risk score calculation required before prescribing. The drug reduced ischemic stroke by a relative 26% without significantly increasing bleeding. FDA approval is anticipated soon, though cost may limit early uptake.
Asundexian cuts stroke risk regardless of baseline cardiovascular risk — and could be a game-changer
A post-hoc analysis of the OCEANIC-STROKE trial, presented at the American Heart Association 2026 Scientific Sessions, confirms that asundexian — a novel factor XIa inhibitor — delivers consistent safety and efficacy benefits across all vascular risk strata. The drug, added on top of antiplatelet therapy in patients with noncardioembolic stroke or high-risk TIA, reduced ischemic stroke by a relative 26% without meaningfully increasing bleeding, regardless of patients' baseline 10-year cardiovascular disease risk.
The finding is clinically significant: because the benefit doesn't vary by risk category, clinicians won't need to calculate a risk score before prescribing — simplifying real-world use. Experts called the overall OCEANIC-STROKE results "truly practice-changing," with neurohospitalists expected to be early adopters. However, cost, insurance coverage, and prior authorization hurdles could slow initial uptake.
By the Numbers
Why it matters: Noncardioembolic strokes make up ~80% of all ischemic strokes, yet treatment options remain limited. Asundexian's consistent benefit across risk groups — with no added bleeding — could meaningfully expand stroke prevention options once FDA approval is granted.
